FDA Extends ZymoGenetics’ rhThrombin Action Date To Jan. 17
ZymoGenetics and commercialization partner Bayer will use the three-month extension to hone plans for “aggressively converting the market,” firm tells “The Pink Sheet” DAILY.
ZymoGenetics and commercialization partner Bayer will use the three-month extension to hone plans for “aggressively converting the market,” firm tells “The Pink Sheet” DAILY.